NLSP NLS Pharmaceutics Ltd

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of December 2023 (Report No. 3)

 

Commission file number: 001-39957

 

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

 

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

CONTENTS

 

Appointment of New Board Members

 

On November 28, 2023, NLS Pharmaceutics Ltd., or the Registrant, announced that Mr. Claudio L. A. Bassetti and Ms. Florence Allouche Aknin have been appointed to serve as members of the Registrant’s board of directors, effective January 1, 2024.

 

On November 28, 2023, the Registrant issued a press release titled: “NLS Pharmaceutics Announces Election of Additional Board Members.” A copy of this press release is furnished herewith as Exhibit 99.1.

 

Auditor Communication

 

On November 10, 2023, the Registrant originally received a letter, or the Original Letter, from its independent auditor, PricewaterhouseCoopers AG, or the Auditor. The Original Letter, which was issued pursuant to Art. 725 and Art. 725b par. 1 of the Swiss Code of Obligations, requested that the Registrant provide a balance sheet at going concern and liquidation values as of October 31, 2023, to assess whether the Registrant’s equity shows an excess of liabilities over assets, with such balance sheet required to be provided no later than November 20, 2023. The Registrant subsequently provided the requested financial information to the Auditor.

 

On December 4, 2023, the Registrant received a subsequent letter, or the Second Letter, from its Auditor advising the Registrant that it reviewed the requested financial information and has determined that for the time being, the Auditor concluded that the Board of Directors has taken the required actions as outlined in the Original Letter.

 

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-262489, 333-268690 and 333-269220), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

EXHIBIT INDEX

 

Exhibit Number		Description of Document
99.1		Press release titled: “NLS Pharmaceutics Announces Election of Additional Board Members.”

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	NLS Pharmaceutics Ltd.
Date: December 4, 2023	By:	/s/ Alexander Zwyer
		Name:	Alexander Zwyer
		Title:	Chief Executive Officer

  

 

Exhibit 99.1

 

NLS Pharmaceutics Announces Election of Additional Board Members

 

·

Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disorders

·

Professor Florence Allouche Aknin, PharmD, MBA is a professor at University Paris City, specializing in pharmaceutical innovation, entrepreneurship and fundraising

 

Zürich, Switzerland, November 28, 2023 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that, subject to final approval of the EGM taking place on Dec. 22, 2023, the board of directors has elected Dr. Florence Allouche Aknin and Dr. Claudio Basetti to join the board effective January 1, 2024.

 

“We are thrilled to have Florence and Claudio join our board of directors," said Alex Zwyer, Chief Executive Officer and Co-founder of NLS Pharmaceutics. "I am confident that Claudio’s vast leadership in narcolepsy and sleep medicine and the fundraising and networking expertise of Florence will prove invaluable as we continue to evolve as a business and continue our mission to develop better therapies to safeguard and empower the brain throughout all stages of life."

 

Professor Claudio L. A. Bassetti, MD

Dr. Basetti received his Doctor of Medicine degree from the University of Basel and trained in Bern and Lausanne, with research fellowships in experimental neurophysiology and Sleep Medicine. In 2000, he was appointed professor of Neurology at the University of Zurich and in 2009, founded the Neurocenter of Southern Switzerland. He is currently Chair of the Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern. He has served as president of the European Neurological Society, European Sleep Research Society, and European Academy of Neurology, among other prominent appointments. He has authored over 560 publications and speaks six languages. A global leader in sleep medicine, he has pioneered studies in sleep disorders and stroke, as well as made fundamental contributions to the etiology, pathophysiology and management of narcolepsy.

 

 

Florence Allouche Aknin, PharmD, MBA

A Doctor of Pharmacy and holding a Master’s in Business Administration, Professor Allouche Aknin began her career as a biologist at AP-HP (Greater Paris Hospitals), managing the tech transfer office for 16 years and creating 75 start-ups. Dr. Allouche Aknin is an expert and mentor at the Paris incubators and has represented French technology internationally. She is a Professor of Pharmacy at the University Paris City and an elected member of the French National Academy of Pharmacy. She is also the President and Founder of Myrpharm Advisors, a start-up studio for the biopharmaceutical industry. In addition, in 2022, Dr. Allouch Aknin launched Sorbonne Venture, a €100M fund dedicated to health technology. She is also Chairwoman of the Board of Directors for PepKon, a French biotechnology company. Among her many awards, Dr. Allouche Aknin was elected “Woman of the Year 2017” by the French financial magazine La Tribune, Women’s trajectory Award 2018 by HEC Paris, and Mercure Entrepreneurs Award 2019 by HEC Paris.

 

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates.  For more information, please visit www.nlspharma.com.

 

For additional information:

Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.

+1 239.682.8500
ml@nls-pharma.com

www.nlspharmaceutics.com

 

 

###

 

 

---